NewAmsterdam Pharma Company N.V.
NASDAQ · us_market
No AI insight generated yet for this ticker.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 8.77M | $280.59M | 0.01% | Added+36.7% | 2026-03-31 |
| Wellington | fundamental | 5.12M | $163.76M | 0.03% | Added+1.6% | 2026-03-31 |
| Viking | long/short | 4.20M | $134.56M | 0.38% | Unchanged | 2026-03-31 |
| StateStreet | passive | 63.1K | $2.02M | 0.00% | Trimmed-7.9% | 2026-03-31 |